Ionis Pharmaceuticals Inc (IONS)-Pharmaceuticals & Healthcare-Deals and Alliances Profile

Ionis Pharmaceuticals Inc (IONS)-Pharmaceuticals & Healthcare-Deals and Alliances Profile


  • Products Id :- GDPH5161D
  • |
  • Pages: 79
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Ionis Pharmaceuticals Inc (Ionis) formerly ISIS Pharmaceuticals, Inc. is clinical stage biopharmaceutical company. It focuses on the discovery and development of RNA-targeted drugs. The company develops first in-class medicines for the treatment of cardiovascular and metabolic disorders, cancer and rare diseases. Ionis develops its products based on its proprietary antisense technology. Its lead product candidates in Phase III development include Kynamro injection being developed in collaboration with Genzyme for the reduction of low-density lipoprotein cholesterol in patients suffering from homozygous familial hypercholesterolemia, or HoFH; Volanesorsen being developed for the treatment of rare, genetic disorders marked by severely high triglyceride levels; IONIS-TTRRx, a first-in-class drug for the treatment of all forms of TTR amyloidosis and Nusinersen being developed for the spinal muscular atrophy (SMA). Ionis is headquartered in Carlsbad, California, the US.

Ionis Pharmaceuticals Inc (IONS)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Ionis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Ionis Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7

Ionis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Ionis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

Ionis Pharmaceuticals Inc, Medical Devices Deals, 2011 to YTD 2017 11

Ionis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12

Ionis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 15

Partnerships 15

Novartis Enters into Option Agreement with Ionis Pharma and Akcea Therapeutics 15

Ionis Pharma Enters into Agreement with Dynacure 16

Ionis Pharma Enters into Agreement with Cystic Fibrosis Foundation 17

Ionis Pharma Partners with University of Texas MD Anderson Cancer Center 17

Biogazelle Enters into Research Agreement with Isis Pharma 18

Isis Pharma Enters into Agreement with Janssen Biotech to Discover and Develop RNA-Targeted Therapeutics 19

AstraZeneca Expands Co-Development Agreement with Isis Pharma 20

Biogen Idec And Isis Pharma Enter Into R&D Agreement To Develop Treatments For Neurological Disorders 21

Roche Enters Into Co-Development Agreement With Isis Pharma For Huntington's Disease Treatment 22

Biogen Idec Enters Into Agreement With Isis Pharma To Develop Antisense Drugs For Neurological Disorders 23

Biogen Idec Enters Into Agreement With Isis Pharma To Develop Antisense Drug For Myotonic Dystrophy 24

Biogen Idec Enters Into Co-Development Agreement With Isis Pharma 25

Licensing Agreements 26

Suzhou Ribo Enters into Licensing Agreement with Ionis Pharma 26

Biogen Exercises Option for Licensing Agreement with Ionis Pharma 27

Janssen Biotech Enters into Licensing Agreement with Ionis Pharma 28

Ionis Pharmaceuticals Enters Into Licensing Agreement with Glaxo Group and GlaxoSmithKline 29

Akcea Therapeutics Enters into Licensing Agreement with Ionis Pharma 30

AstraZeneca Enters into Licensing Agreement with Isis Pharma 31

Bayer HealthCare Expands Licensing Agreement with Ionis Pharma 32

Isis Pharma Enters Into Licensing Agreement With AstraZeneca 33

Kastle Therapeutics Acquires Global Rights for KYNAMRO Injection from Ionis Pharma 35

Alnylam Pharma Enters into Licensing Agreement with Isis Pharma 36

Isis Pharma Enters into Licensing Agreement with Alnylam Pharma 37

Xenon Pharma Exercises Option For Licensing Agreement With Isis Pharma For Antisense Drug XEN701 38

GlaxoSmithKline Amends Licensing Agreement With Isis Pharma For ISIS-TTRRx 39

Equity Offering 40

Akcea Therapeutics Raises USD143.8 Million in IPO 40

Akcea Therapeutics Raises USD50 Million in Private Placement of Shares 42

Ionis Pharma Files Registration Statement for Public Offering of Shares for up to USD68.7 Million 42

Akcea Therapeutics Raises USD100 Million in Private Placement of Series A Preferred Stock 43

Isis Pharma Completes Public Offering Of Shares For USD182.7 Million 44

Debt Offering 45

Isis Pharma Completes Private Placement of Notes for USD500 Million 45

Isis Pharma Completes Private Placement Of Convertible Senior Notes Due 2019 For USD201 Million 47

Acquisition 48

Pfizer Completes Acquisition Of Skin Scarring Drugmaker Excaliard Pharma 48

Ionis Pharmaceuticals Inc-Key Competitors 51

Key Employees 52

Locations And Subsidiaries 53

Head Office 53

Other Locations & Subsidiaries 53

Recent Developments 54

Financial Announcements 54

May 09, 2017: Ionis Reports Financial Results and Highlights for First Quarter 2017 54

Feb 28, 2017: Ionis' 2016 Financial Results Outperform Financial Guidance 56

Jan 06, 2017: Ionis Pharmaceuticals Significantly Improves Upon 2016 Financial Guidance 60

Nov 09, 2016: Ionis Pharmaceuticals Reports Financial Results and Highlights for Third Quarter 2016 61

Aug 09, 2016: Ionis Pharmaceuticals Reports Financial Results and Highlights for Second Quarter 2016 63

May 04, 2016: Ionis Reports Financial Results and Highlights for First Quarter 2016 65

Feb 25, 2016: Ionis' 2015 Financial Results Outperform Projections 67

Legal and Regulatory 71

Mar 22, 2016: Ionis Pharmaceuticals and Merck Receive Positive Verdict on Gilead HCV Drug Patent Case 71

Product Approvals 72

Jan 05, 2016: Ionis Pharmaceuticals Receives Orphan Drug Designation from the US FDA for IONIS-HTT Rx for the Treatment of Patients with Huntington Disease 72

Clinical Trials 73

Jul 07, 2016: Ionis Pharmaceuticals Reports Positive Clinical Data on IONIS-TTR Rx at the XV International Symposium on Amyloidosis 73

May 26, 2016: Ionis Pharmaceuticals Provides Update on IONIS-TTR Rx Program 75

Apr 07, 2016: Ionis Pharmaceuticals Provides Update on IONIS-TTRRX Program 76

Jan 13, 2016: Ionis Pharmaceuticals Announces that GSK has Initiated a Phase 1 Study of IONIS-HBV-L Rx 77

Other Significant Developments 78

Jan 11, 2016: Ionis Pharmaceuticals Revises 2015 Financial Guidance and Provides Pipeline Update in Conjunction with J.P. Morgan Conference 78

Appendix 79

Methodology 79

About GlobalData 79

Contact Us 79

Disclaimer 79

List of Figures

Ionis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1

Ionis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1

Ionis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1

Ionis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1

Ionis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Ionis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 7

Ionis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Ionis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

Ionis Pharmaceuticals Inc, Medical Devices Deals, 2011 to YTD 2017 11

List of Tables

Ionis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 1

Ionis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Ionis Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7

Ionis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Ionis Pharmaceuticals Inc, Deals By Therapy Area, 2011 to YTD 2017 9

Ionis Pharmaceuticals Inc, Medical Devices Deals, 2011 to YTD 2017 11

Ionis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12

Novartis Enters into Option Agreement with Ionis Pharma and Akcea Therapeutics 15

Ionis Pharma Enters into Agreement with Dynacure 16

Ionis Pharma Enters into Agreement with Cystic Fibrosis Foundation 17

Ionis Pharma Partners with University of Texas MD Anderson Cancer Center 17

Biogazelle Enters into Research Agreement with Isis Pharma 18

Isis Pharma Enters into Agreement with Janssen Biotech to Discover and Develop RNA-Targeted Therapeutics 19

AstraZeneca Expands Co-Development Agreement with Isis Pharma 20

Biogen Idec And Isis Pharma Enter Into R&D Agreement To Develop Treatments For Neurological Disorders 21

Roche Enters Into Co-Development Agreement With Isis Pharma For Huntington's Disease Treatment 22

Biogen Idec Enters Into Agreement With Isis Pharma To Develop Antisense Drugs For Neurological Disorders 23

Biogen Idec Enters Into Agreement With Isis Pharma To Develop Antisense Drug For Myotonic Dystrophy 24

Biogen Idec Enters Into Co-Development Agreement With Isis Pharma 25

Suzhou Ribo Enters into Licensing Agreement with Ionis Pharma 26

Biogen Exercises Option for Licensing Agreement with Ionis Pharma 27

Janssen Biotech Enters into Licensing Agreement with Ionis Pharma 28

Ionis Pharmaceuticals Enters Into Licensing Agreement with Glaxo Group and GlaxoSmithKline 29

Akcea Therapeutics Enters into Licensing Agreement with Ionis Pharma 30

AstraZeneca Enters into Licensing Agreement with Isis Pharma 31

Bayer HealthCare Expands Licensing Agreement with Ionis Pharma 32

Isis Pharma Enters Into Licensing Agreement With AstraZeneca 33

Kastle Therapeutics Acquires Global Rights for KYNAMRO Injection from Ionis Pharma 35

Alnylam Pharma Enters into Licensing Agreement with Isis Pharma 36

Isis Pharma Enters into Licensing Agreement with Alnylam Pharma 37

Xenon Pharma Exercises Option For Licensing Agreement With Isis Pharma For Antisense Drug XEN701 38

GlaxoSmithKline Amends Licensing Agreement With Isis Pharma For ISIS-TTRRx 39

Akcea Therapeutics Raises USD143.8 Million in IPO 40

Akcea Therapeutics Raises USD50 Million in Private Placement of Shares 42

Ionis Pharma Files Registration Statement for Public Offering of Shares for up to USD68.7 Million 42

Akcea Therapeutics Raises USD100 Million in Private Placement of Series A Preferred Stock 43

Isis Pharma Completes Public Offering Of Shares For USD182.7 Million 44

Isis Pharma Completes Private Placement of Notes for USD500 Million 45

Isis Pharma Completes Private Placement Of Convertible Senior Notes Due 2019 For USD201 Million 47

Pfizer Completes Acquisition Of Skin Scarring Drugmaker Excaliard Pharma 48

Ionis Pharmaceuticals Inc, Key Competitors 51

Ionis Pharmaceuticals Inc, Key Employees 52

Ionis Pharmaceuticals Inc, Subsidiaries 53

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Ionis Pharmaceuticals Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license

Single User License
USD 250 INR 16235
Site License
USD 500 INR 32470
Corporate User License
USD 750 INR 48705

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com